Hannah Robinson
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Hannah Robinson is an Assistant Professor at the University of Colorado Cancer Center in the United States. Her research focuses on colorectal cancer, with particular interest in immunotherapy, biomarker testing, and comprehensive genomic profiling. Recent publications include studies on the effectiveness of combining pembrolizumab with other therapies in refractory microsatellite-stable colorectal cancer and real-world analyses of anti-EGFR treatments.
Articles (18)
Triple therapy (ALX90, cetuximab, and pembrolizumab) activates human T cells and slows tumor growth of CRC307P colorectal cancer MSS PDX in HIS-BRGS mice. A, SGRs of CRC307P in HIS-BRGS mice among treatment groups: vehicle (V), ALX90 (A), cetuximab (C) + pembrolizumab (CP), ACP (ALX90 + cetuximab + pembrolizumab), LC, and ACP + LC. B, Human immune infiltration in CRC307P tumors in HIS-BRGS mice. Left, frequency of human immune (human CD45 + of mouse + human CD45 + ). Middle, number of human T cells. Right, frequency of CD8 + T cells among CD3 + cells. C, IFNγ+ and TNFα+ cytotoxic CD4 + and CD8 + tumor-infiltrating T cells. D, Immunophenotype correlation with tumor growth (SGR) among triple therapy (ACP, red), triple therapy following LC treatments (ACP + LC, purple), and all mice treated with triple therapy with or without LC (ACP ± LC, black). Statistics of linear correlation are provided; *, P P
Year:
2025
Pharmacodynamic analyses. A, Multiplex IHC of archival tumor tissue from one patient with disease progression and one patient with PR; B, Percent change (cycle 3 day 1 compared with baseline) in peripheral blood effector CD4 + (CD4 + CD3 + CD45RA − CD45RO − ) and CD8 + (CD8 + CD3 + CD45RA − CD45RO − ) T cells, granzyme B+ EOMES+ CD4 + (CD4 + CD3 + GrzB+EOMES+) and CD8 + (CD8 + CD3 + GrzB+EOMES+) T cells, and activated monocytes (CD11c + HLADR+CD16 + ) in patients with controlled disease (PR or stable disease) as best response compared with disease progression; ( C ) TCR diversity at baseline and after treatment (cycle 3 day 1 or cycle 4 day 1). GrzB, granzyme B. Statistics of linear correlation are provided; *, P
Year:
2025
Role of mouse myeloid cells in CRC307P-bearing HIS-BRGS mice treated with combinations of ALX90, cetuximab, pembrolizumab, and LC. A, Flow cytometric gating strategy for quantification of mouse (mCD45 + ) myeloid populations: PMNs (Ly6G+), M1 (CD38 + ) and M2 (CD206 + ) macrophages (MO: F4/80+), and expression of mouse MHC class I and class II. B, Quantification of human (left, CD11b + CD14 + , CD33 + , or CD11c + ) and mouse (right, mCD45 + ) myeloid populations in tumors of HIS-CRC307P-BRGS mice among treatment groups: vehicle (V), ALX90 (A), cetuximab (C) + pembrolizumab (CP), ACP (ALX90 + cetuximab + pembrolizumab), LC, and ACP + LC. C, Ratios of PMN/MO and M1/M2 of F4/80 macrophages among mouse myeloid cells. D, Correlation of mouse myeloid populations with tumor growth (SGR) among triple therapy (ACP, top) and triple therapy following LC treatments (ACP + LC, bottom). Statistics of linear correlation are provided; *, P P P
Year:
2025
Supplementary Figure S3. Triple therapy (ALX90, cetuximab, and pembrolizumab) activates human T cells and slows tumor growth of CRC307P CRC MSS PDX in HIS-BRGS mice with liposomal clodronate treatment (LC).
Year:
2025
Depth and duration of response by subject. A, Waterfall plot of best percent change in aggregate size of target lesions. B, Swimmer plot of duration of response. As of the data cutoff, subject 36-002 remained on study. In ( A ), subject 30-002 is not included due to a 35% decrease in target lesions but unequivocal progression in nontarget lesions. PI, principal investigator.
Year:
2025
Purpose: In this preclinical human immune system patient-derived xenograft (HIS-PDX) model and phase II clinical trial, we assessed evorpacept (anti-CD47 engineered fusion protein with inactive Fc), cetuximab, and pembrolizumab (triple therapy) in microsatellite-stable (MSS) colorectal cancer. Patients and Methods: HIS BALB/c-Rag2 null Il2rγ null Sirpα NOD mice with PDXs were treated with triple therapy or its components. Patients with refractory MSS colorectal cancer were treated with triple therapy in a safety run-in (stage 1) followed by expansion (stage 2, planned N = 42). The co-primary objectives were to determine the recommended dose of evorpacept and objective response rate (vs. historic control). Results: In HIS-PDX mice, triple therapy decreased the growth of MSS colorectal cancer tumors and increased tumor-infiltrating CD8 + T cells. Sixteen patients were treated on the clinical trial across two evorpacept dose levels: N = 12 in stage 1 and N = 4 in stage 2. Trial enrollment was terminated early because of safety concerns (one treatment-related grade 5 event each of hemophagocytic lymphohistiocytosis and cytokine release syndrome). Otherwise, the adverse event profile was as expected. Among all patients, the objective response rate was 6.3%; formal hypothesis testing was not performed. The disease control rate was 12.5%, the median progression-free survival was 2.3 months, and the median overall survival was 10.9 months. Blood- and tumor-based clinical trial correlative analyses identified innate and adaptive immune system activation. Conclusions: Whereas triple therapy demonstrated evidence of efficacy in refractory MSS colorectal cancer, safety concerns halted enrollment. Further investigation is necessary to determine the optimal use of CD47-targeted therapies in MSS colorectal cancer. Significance: Evorpacept, cetuximab, and pembrolizumab demonstrated antitumor activity in a preclinical HIS-PDX model and clinical trial in refractory MSS colorectal cancer; however, immune-related adverse events prompted early termination of study enrollment. Evidence of innate and adaptive antitumor immune activation was identified. The role of SIRPα/CD47 blockade in the treatment of MSS colorectal cancer needs to be further elucidated in future trials.
Year:
2025
Year:
2024
3552 Background: Anti-EGFR therapies including cetuximab and panitumumab are recommended in frontline or later-line treatment regimens for left-sided metastatic colorectal cancer (mCRC) lacking mutations in RAS or BRAF. Here we report patterns of anti-EGFR therapy use in patients with mCRC diagnosed between 2013 and 2023. Methods: This study used the nationwide Flatiron Health electronic health record (EHR)-derived de-identified database, which contains patient-level data originating from approximately 280 cancer clinics in the United States (~800 sites of care).Adult patients diagnosed with mCRC from January 1, 2013 to April 28, 2023 who received at least 1 line of treatment were included. The percentage of patients who received anti-EGFR agents based on biomarker indication and primary tumor sidedness (PTS) was determined. PTS was assessed by ICD codes, with left-sided disease defined as tumors originating from the splenic flexure to the rectum. Univariate and multivariable analyses were performed to evaluate for factors associated with utilization of biomarker-directed anti-EGFR therapy. Results: A total of 25,937 patients were included in this analysis. Among these, 3,425 (13.2%) had a confirmed indication for anti-EGFR therapy, based on the presence of left-sided disease and documented KRAS, NRAS,and BRAFwildtype status (Cohort 1). In contrast, 15,015 (57.9%) patients had a documented RASor BRAF mutation and/or right-sided disease (Cohort 2). Anti-EGFR therapy was included in frontline treatment for 19.7% of patients in Cohort 1 versus 3.3% of patients in Cohort 2. Anti-EGFR therapy was included in any-line treatment for 56.6% of patients in Cohort 1 versus 12.1% of patients in Cohort 2. Patients in Cohort 1 were less likely to receive anti-EGFR therapy in any treatment line if they were ≥ 75 versus < 45 years old at diagnosis (odds ratio [OR] 0.72, p = 0.027), had a primary rectal versus colon cancer (OR 0.87, p = 0.045), or were diagnosed at a later timepoint. For instance, while 72.4% of Cohort 1 patients diagnosed between 2013-2015 received anti-EGFR therapy, only 63.9% (OR 0.68, p = 0.05), 59.5% (OR 0.57, p < 0.001), and 46.7% (OR 0.34, p < 0.001) of patients diagnosed between 2016-2017, 2018-2019, and 2020-2023 received anti-EGFR therapy, respectively. Patient sex, race, ethnicity, practice setting, socioeconomic index, and performance status were not associated with anti-EGFR therapy use. Conclusions: Based on results from the Flatiron Health database, use of anti-EGFR therapy is enriched among patients with biomarker-based indications for treatment. Notably, anti-EGFR therapy was employed in only 56.6% of patients with RAS and RAF wildtype, left-sided mCRC, with decreased use observed from 2013 to 2023.
Year:
2024
3530 Background: Single-agent anti-PD-1/PD-L1 drugs are ineffective in MSS CRC. E is an engineered protein (high-affinity CD47-blocker fused to an inactive IgG Fc region), which blocks the CD47/SIRPα innate immune inhibitory phagocytosis checkpoint expressed on CRC and phagocytes, respectively. Preclinical evidence suggests ECP may be effective in MSS CRC. Methods: This phase 2, single-arm, two-stage, multicenter, investigator-initiated trial of E (15 or 10 mg/kg weekly at dose level [DL] 1 and -1, respectively), C (400 mg/m 2 then 250 mg/m 2 weekly), and P (200 mg every 3 weeks) in 21-day cycles enrolled patients with MSS CRC, regardless of tumor sidedness and RAS/BRAF status, refractory to ≥ 2 prior lines of therapy, including EGFR inhibitor if indicated (NCT05167409). All patients in both Stage 1 (safety run-in) and Stage 2 (expansion) received ECP until progression or unacceptable toxicity. The co-primary objectives were to determine the recommended dose (RD) of E with CP and objective response rate (ORR) by RECIST v1.1 (by one-sided exact test with α=0.05, H 0 p ≤ 3% [historical controls], H A p ≥ 15%; power is 87% with N=48). Results: The safety-evaluable population included 16 patients, of whom 69% were male and median age 53 years. The primary tumor was in the right, left, and transverse colorectum in 31%, 31%, and 6% of patients, and was unknown in 31%. Mutations in KRAS, NRAS, and BRAF genes were present in 38%, 6%, and 0% of patients. The median number of prior lines of therapy was 3, including prior EGFR inhibitor in 44%. In Stage 1, 9 and 3 patients were enrolled at E DL1 and DL-1, respectively. E DL1 was established as the RD for Stage 2, in which 4 patients were enrolled. The most common any-grade treatment-emergent adverse events were headache (32%), fatigue (26%), anemia (21%), diarrhea (21%), dyspnea (16%), abdominal pain (16%), nausea/vomiting (16% each), and acneiform rash (16%). There were two on-study deaths assessed as related to all three study drugs (hemophagocytic lymphohistiocytosis and cytokine release syndrome; 1 each). While both are known associations with checkpoint inhibitors, other significant factors contributing to these event outcomes included cancer progression with high tumor burden in the former and patient decision to transition to comfort care in the latter. In the safety-evaluable population, ORR was 6.3% (1 ongoing partial response, 95% confidence interval [CI] 0.2-30.2%), disease control rate was 12.5% (95% CI 1.6-38.4%), median progression-free survival was 2.6 months (mo; 95% CI 2.1-2.9 mo), and median overall survival was 10.9 mo (95% CI 3.3 mo-infinity). Formal hypothesis testing was not performed. Conclusions: Further dose optimization of ECP is needed to establish a RD in the refractory MSS CRC population. While initial activity was seen, at the DLs evaluated, criteria for study termination were met. Clinical trial information: NCT05167409 .
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (10)
Junxiao Hu
Assistant Professor
University of Colorado Anschutz Medical Campus
Wells Messersmith
Professor and Cancer Center Director
University of Colorado Cancer Center
Christopher Lieu
Associate Professor
University of Denver
Adrie van Bokhoven
Associate Professor
University of Colorado
Todd Pitts
-
Robert Lentz
Assistant Professor
University of Colorado Cancer Center
Sunnie S. Kim
University of Colorado Anschutz Medical Campus
Howard S Hochster
Rutgers University
Alexis Leal
Assistant Professor of Medicine
University of Colorado Anschutz Medical Campus
Julie Lang
Associate Research Professor
University of Colorado Anschutz Medical Campus
Make your next move.
Prepare your application
Review drafts before you send them.